[Solved] NR546 Week 3: Antipsychotic Medications Table 

COURSE:

NR546 – Advanced Pharmacology: Psychopharmacology

Requirements

Follow these guidelines when completing each component of the assignment. Contact your course faculty if you have questions.

General Instructions

Download the Week 3 Medication Table. and complete the required information using the template.

Include the following sections (detailed criteria listed below and in the grading rubric)

  1. For each medication listed, complete the following:
    1. Provide indication, target symptoms, potency, and affected neurotransmitters.
    2. Include half-life and CYP 450 enzyme information.
    3. List notable side effects.
    4. Link notable side effects to the associated pathway or neurotransmitter.

Submit your completed medication table to the Week 3 dropbox

 

Solution

Drug name Indication

Target symptoms: state if positive or negative effect Potency (if noted. receptor occupancy if noted) Neurotransmitter(s) affected

 Half-life (T1/2), metabolism (CYP 450 enzyme) Notable side effects (associate to pathway or NT)
Typical antipsychotics (conventional)
Haloperidol Target symptoms:

signs and symptoms of psychotic illnesses Tourette’s Syndrome: vocal utterances and tics Second-line therapy for children with significant behavioral issues who are irrational, erratic, or very excitable Short-term, second-line therapy for hyperactive kids Treatment of people with schizophrenia who need continuous parenteral antipsychotic medication Manic Depressive Disorder Difficulties with behavior with dementias (When using lorazepam) Delirium Positive signs of psychosis, acting aggressively or violently

 

Potency: High potency first-generation

Neurotransmitter(s) affected:

reduces aggressive, explosive, and hyperactive behaviors as well as positive signs of psychosis by blocking dopamine 2 receptors. improves Tourette’s syndrome symptoms and other symptoms by blocking dopamine 2 receptors in the nigrostriatal pathway.

 

 Half-Life: Haldol decanoate: approximately 3

weeks Oral: 12-38 hours

 

Metabolism: CYP1A2, CYP2D6, CYP3A4

 •Neuroleptic-induced deficit syndrome

•Akathisia

•Drug-induced parkinsonism

•Tardive dyskinesia, dystonia

•Irreversible involuntary dyskinetic movements

•Galactorrhea, amenorrhea • Dizziness, sedation

•Dry mouth

•Constipation

•Urinary retention

•Blurred vision

•Decreased sweating

•Hypotension

•Tachycardia

•Hypertension

•Weight gain

………………………………………………….$5